{"id":436,"date":"2023-09-14T15:26:37","date_gmt":"2023-09-14T13:26:37","guid":{"rendered":"https:\/\/cfnorge.bwod.dev\/?page_id=436"},"modified":"2025-11-10T14:59:08","modified_gmt":"2025-11-10T13:59:08","slug":"slik-er-behadlingen-for-cf-med-kaftrio","status":"publish","type":"page","link":"https:\/\/www.cfnorge.no\/en\/cystisk-fibrose\/slik-er-behadlingen-for-cf-med-kaftrio\/","title":{"rendered":"Slik er behadlingen for CF med Kaftrio"},"content":{"rendered":"<p>[et_pb_section fb_built=&raquo;1&#8243; next_background_color=&raquo;#ffffff&raquo; _builder_version=&raquo;4.21.0&#8243; _module_preset=&raquo;default&raquo; background_color=&raquo;gcid-9e2f3af2-1007-4221-b250-8e35d98c5991&#8243; top_divider_color=&raquo;gcid-26e97d0d-b127-4ce1-b597-0df3fb01df24&#8243; top_divider_height=&raquo;55px&raquo; top_divider_flip=&raquo;vertical&raquo; bottom_divider_style=&raquo;wave&raquo; locked=&raquo;off&raquo; global_colors_info=&raquo;{%22gcid-26e97d0d-b127-4ce1-b597-0df3fb01df24%22:%91%22top_divider_color%22%93,%22gcid-9e2f3af2-1007-4221-b250-8e35d98c5991%22:%91%22background_color%22%93}&raquo;][et_pb_row _builder_version=&raquo;4.21.0&#8243; _module_preset=&raquo;default&raquo; custom_padding=&raquo;11px||4px|||&raquo; locked=&raquo;off&raquo; global_colors_info=&raquo;{}&raquo;][et_pb_column type=&raquo;4_4&#8243; _builder_version=&raquo;4.21.0&#8243; _module_preset=&raquo;default&raquo; global_colors_info=&raquo;{}&raquo;][et_pb_text _builder_version=&raquo;4.21.0&#8243; _module_preset=&raquo;default&raquo; header_font=&raquo;Poppins|600|||||||&raquo; header_text_color=&raquo;gcid-26e97d0d-b127-4ce1-b597-0df3fb01df24&#8243; custom_margin=&raquo;0px||0px||false|false&raquo; custom_padding=&raquo;0px||0px||false|false&raquo; global_colors_info=&raquo;{%22gcid-26e97d0d-b127-4ce1-b597-0df3fb01df24%22:%91%22header_text_color%22%93}&raquo;]<\/p>\n<h1>Behandling for CF med Kaftrio<\/h1>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=&raquo;4.21.0&#8243; _module_preset=&raquo;default&raquo; custom_margin=&raquo;0px|auto|68px|auto|false|false&raquo; custom_padding=&raquo;0px||||false|false&raquo; locked=&raquo;off&raquo; global_colors_info=&raquo;{}&raquo;][et_pb_column type=&raquo;4_4&#8243; _builder_version=&raquo;4.21.0&#8243; _module_preset=&raquo;default&raquo; global_colors_info=&raquo;{}&raquo;][et_pb_text _builder_version=&raquo;4.21.0&#8243; _module_preset=&raquo;default&raquo; text_font=&raquo;Poppins|300|||||||&raquo; text_text_color=&raquo;gcid-26e97d0d-b127-4ce1-b597-0df3fb01df24&#8243; text_font_size=&raquo;16px&raquo; text_line_height=&raquo;1.8em&raquo; global_colors_info=&raquo;{%22gcid-26e97d0d-b127-4ce1-b597-0df3fb01df24%22:%91%22text_text_color%22%93}&raquo;]Kaftrio\/Kalydeco er en innovativ \u00e5rsaks-korrigerende behandling for cystisk fibrose. Behandlingen viser opptil 14 prosentpoeng bedring i lungekapasitet i en studie blant personer med CF med minst en 508del-mutasjon i CFTR-genet.<\/p>\n<p>Kaftrio\/Kalydeco ble endelig godkjent offentlig finansiert i Norge 25. april 2022 ved et vedtak i Beslutningsforum. De godkjente ogs\u00e5 Kaftrio for barn i aldersgruppen 2-6 \u00e5r 27. mai 2024. Kaftrio kan n\u00e5 kan benyttes for barn med cystisk fibrose som har minst \u00e9n F508del-mutasjon fra 1. juli 2024.<\/span>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&raquo;1&#8243; _builder_version=&raquo;4.21.0&#8243; _module_preset=&raquo;default&raquo; global_colors_info=&raquo;{}&raquo; min_height__hover_enabled=&raquo;off|desktop&raquo;][et_pb_row column_structure=&raquo;1_3,1_3,1_3&#8243; use_custom_gutter=&raquo;on&raquo; gutter_width=&raquo;2&#8243; _builder_version=&raquo;4.21.0&#8243; _module_preset=&raquo;default&raquo; custom_padding=&raquo;0px|||||&raquo; locked=&raquo;off&raquo; global_colors_info=&raquo;{}&raquo;][et_pb_column type=&raquo;1_3&#8243; _builder_version=&raquo;4.21.0&#8243; _module_preset=&raquo;default&raquo; global_colors_info=&raquo;{}&raquo;][et_pb_toggle title=&raquo;Hva er Kaftrio\/Kalydeco?&raquo; open_toggle_text_color=&raquo;gcid-edcc47c2-e936-4ba2-8e6c-8ca8cb2c2a05&#8243; open_toggle_background_color=&raquo;gcid-9e2f3af2-1007-4221-b250-8e35d98c5991&#8243; closed_toggle_background_color=&raquo;gcid-9e2f3af2-1007-4221-b250-8e35d98c5991&#8243; icon_color=&raquo;gcid-edcc47c2-e936-4ba2-8e6c-8ca8cb2c2a05&#8243; toggle_icon=&raquo;&#x22;||divi||400&#8243; use_icon_font_size=&raquo;on&raquo; icon_font_size=&raquo;18px&raquo; open_icon_color=&raquo;gcid-edcc47c2-e936-4ba2-8e6c-8ca8cb2c2a05&#8243; open_toggle_icon=&raquo;&#x21;||divi||400&#8243; _builder_version=&raquo;4.21.0&#8243; _module_preset=&raquo;default&raquo; title_text_color=&raquo;gcid-edcc47c2-e936-4ba2-8e6c-8ca8cb2c2a05&#8243; title_font=&raquo;|600|||||||&raquo; body_text_color=&raquo;gcid-26e97d0d-b127-4ce1-b597-0df3fb01df24&#8243; body_link_text_color=&raquo;gcid-edcc47c2-e936-4ba2-8e6c-8ca8cb2c2a05&#8243; custom_padding=&raquo;35px||35px||false|false&raquo; border_width_all=&raquo;0px&raquo; locked=&raquo;off&raquo; global_colors_info=&raquo;{%22gcid-edcc47c2-e936-4ba2-8e6c-8ca8cb2c2a05%22:%91%22icon_color%22,%22open_toggle_text_color%22,%22title_text_color%22,%22body_link_text_color%22,%22open_icon_color%22%93,%22gcid-26e97d0d-b127-4ce1-b597-0df3fb01df24%22:%91%22body_text_color%22%93,%22gcid-9e2f3af2-1007-4221-b250-8e35d98c5991%22:%91%22closed_toggle_background_color%22,%22open_toggle_background_color%22%93}&raquo;]<\/p>\n<p>Kaftrio\/Kalydeco er en innovativ \u00e5rsaks-korrigerende behandling for cystisk fibrose.<\/p>\n<p>Medisinen best\u00e5r av de tre forskjellige virkestoffene elexacaftor, tezacaftor og ivacaftor.<\/p>\n<p>Sammen p\u00e5virker disse stoffene CFTR-proteinet som for\u00e5rsaker cystisk fibrose. Denne type behandling kalles derfor CFTR-modulator<\/p>\n<p><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:0,&quot;335559739&quot;:150}\"><\/span><\/p>\n<ul>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"1\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559684&quot;:-2,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:[8226],&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;multilevel&quot;}\" aria-setsize=\"-1\" data-aria-posinset=\"1\" data-aria-level=\"1\"><a href=\"https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/kaftrio-epar-product-information_no.pdf\"><span data-contrast=\"none\">Preparatomtale Kaftrio p\u00e5 NORSK<\/span><\/a><span data-contrast=\"none\">\u202f(informasjon om aktuelle minimalfunksjon-mutasjoner som har v\u00e6rt med i studiene finner du under punkt 5.1, side 11-12)<\/span><span data-ccp-props=\"{&quot;134233117&quot;:true,&quot;134233118&quot;:true}\">\u00a0<\/span><\/li>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"1\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559684&quot;:-2,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:[8226],&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;multilevel&quot;}\" aria-setsize=\"-1\" data-aria-posinset=\"2\" data-aria-level=\"1\"><a href=\"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/kaftrio\"><span data-contrast=\"none\">EMA: fullstendig godkjenningsinformasjon KAFTRIO<\/span><\/a><span data-ccp-props=\"{&quot;134233117&quot;:true,&quot;134233118&quot;:true}\">\u00a0<\/span><\/li>\n<\/ul>\n<p>[\/et_pb_toggle][et_pb_toggle title=&raquo;N\u00e5r man ikke kan bruke Kaftrio&raquo; open_toggle_text_color=&raquo;gcid-edcc47c2-e936-4ba2-8e6c-8ca8cb2c2a05&#8243; open_toggle_background_color=&raquo;gcid-9e2f3af2-1007-4221-b250-8e35d98c5991&#8243; closed_toggle_background_color=&raquo;gcid-9e2f3af2-1007-4221-b250-8e35d98c5991&#8243; icon_color=&raquo;gcid-edcc47c2-e936-4ba2-8e6c-8ca8cb2c2a05&#8243; toggle_icon=&raquo;&#x22;||divi||400&#8243; use_icon_font_size=&raquo;on&raquo; icon_font_size=&raquo;18px&raquo; open_icon_color=&raquo;gcid-edcc47c2-e936-4ba2-8e6c-8ca8cb2c2a05&#8243; open_toggle_icon=&raquo;&#x21;||divi||400&#8243; _builder_version=&raquo;4.21.0&#8243; _module_preset=&raquo;default&raquo; title_text_color=&raquo;gcid-edcc47c2-e936-4ba2-8e6c-8ca8cb2c2a05&#8243; title_font=&raquo;|600|||||||&raquo; body_text_color=&raquo;gcid-26e97d0d-b127-4ce1-b597-0df3fb01df24&#8243; body_link_text_color=&raquo;gcid-edcc47c2-e936-4ba2-8e6c-8ca8cb2c2a05&#8243; custom_padding=&raquo;35px||35px||false|false&raquo; border_width_all=&raquo;0px&raquo; locked=&raquo;off&raquo; global_colors_info=&raquo;{%22gcid-edcc47c2-e936-4ba2-8e6c-8ca8cb2c2a05%22:%91%22icon_color%22,%22open_toggle_text_color%22,%22title_text_color%22,%22body_link_text_color%22,%22open_icon_color%22%93,%22gcid-26e97d0d-b127-4ce1-b597-0df3fb01df24%22:%91%22body_text_color%22%93,%22gcid-9e2f3af2-1007-4221-b250-8e35d98c5991%22:%91%22closed_toggle_background_color%22,%22open_toggle_background_color%22%93}&raquo;]<\/p>\n<p>For de som ikke kan bruke Kaftrio, kan det v\u00e6re ekstra vanskelig i et fellesskap preget av kollektiv jubel. Som NFCF medlem,\u00a0 Bernhard (30) beskriver s\u00e5 godt: &laquo;Det kan f\u00f8les som \u00e5 st\u00e5 igjen p\u00e5 busstoppet n\u00e5r bussen har kj\u00f8rt.&raquo; Klikk p\u00e5 lenken under for \u00e5 lese mer om dette viktige temaet, og hvordan NFCF sammen med internasjonale samarbeidspartnere jobber for \u00e5 sikre fremtidige behandlingsmuligheter for flere med CF.<\/p>\n<p><a href=\"https:\/\/www.cfnorge.no\/a-sta-igjen-pa-busstoppet-nar-man-ikke-kan-bruke-kaftrio\/?fbclid=IwY2xjawFH8n1leHRuA2FlbQIxMQABHYX6owCHBonU5ovx1z0cJXZ2BM6yv2FEgnsC2st44Gmmc9BYyDZi2JA-kw_aem_9Y9sWwtt65dyBcy1cdFhrQ\">\u00c5 st\u00e5 igjen p\u00e5 busstoppet &#8211; N\u00e5r man ikke kan\u00a0 bruke Kaftrio\u00a0<\/a><\/p>\n<p>[\/et_pb_toggle][\/et_pb_column][et_pb_column type=&raquo;1_3&#8243; _builder_version=&raquo;4.21.0&#8243; _module_preset=&raquo;default&raquo; global_colors_info=&raquo;{}&raquo;][et_pb_toggle title=&raquo;Hvem kan f\u00e5 Kaftrio\/Kalydeco?&raquo; open_toggle_text_color=&raquo;gcid-edcc47c2-e936-4ba2-8e6c-8ca8cb2c2a05&#8243; open_toggle_background_color=&raquo;gcid-9e2f3af2-1007-4221-b250-8e35d98c5991&#8243; closed_toggle_background_color=&raquo;gcid-9e2f3af2-1007-4221-b250-8e35d98c5991&#8243; icon_color=&raquo;gcid-edcc47c2-e936-4ba2-8e6c-8ca8cb2c2a05&#8243; toggle_icon=&raquo;&#x22;||divi||400&#8243; use_icon_font_size=&raquo;on&raquo; icon_font_size=&raquo;18px&raquo; open_icon_color=&raquo;gcid-edcc47c2-e936-4ba2-8e6c-8ca8cb2c2a05&#8243; open_toggle_icon=&raquo;&#x21;||divi||400&#8243; _builder_version=&raquo;4.21.0&#8243; _module_preset=&raquo;default&raquo; title_text_color=&raquo;gcid-edcc47c2-e936-4ba2-8e6c-8ca8cb2c2a05&#8243; title_font=&raquo;|600|||||||&raquo; body_text_color=&raquo;gcid-26e97d0d-b127-4ce1-b597-0df3fb01df24&#8243; body_link_text_color=&raquo;gcid-edcc47c2-e936-4ba2-8e6c-8ca8cb2c2a05&#8243; custom_padding=&raquo;35px||35px||false|false&raquo; title_line_height_tablet=&raquo;&raquo; title_line_height_phone=&raquo;1.4em&raquo; title_line_height_last_edited=&raquo;on|phone&raquo; border_width_all=&raquo;0px&raquo; locked=&raquo;off&raquo; global_colors_info=&raquo;{%22gcid-edcc47c2-e936-4ba2-8e6c-8ca8cb2c2a05%22:%91%22icon_color%22,%22open_toggle_text_color%22,%22title_text_color%22,%22body_link_text_color%22,%22open_icon_color%22%93,%22gcid-26e97d0d-b127-4ce1-b597-0df3fb01df24%22:%91%22body_text_color%22%93,%22gcid-9e2f3af2-1007-4221-b250-8e35d98c5991%22:%91%22open_toggle_background_color%22,%22closed_toggle_background_color%22%93}&raquo;]<\/p>\n<div class=\"flex flex-grow flex-col max-w-full\">\n<div data-message-author-role=\"assistant\" data-message-id=\"5d0ab7be-8daf-42db-a6cf-96ae7efeced8\" dir=\"auto\" class=\"min-h-[20px] text-message flex flex-col items-start whitespace-pre-wrap break-words [.text-message+&amp;]:mt-5 juice:w-full juice:items-end overflow-x-auto gap-2\">\n<div class=\"flex w-full flex-col gap-1 juice:empty:hidden juice:first:pt-[3px]\">\n<div class=\"markdown prose w-full break-words dark:prose-invert light\">\n<p>Kaftrio\/Kalydeco er godkjent til bruk for mennesker med cystisk fibrose (CF) som er 6 \u00e5r eller eldre, og som har \u00e9n F508del-mutasjon og \u00e9n minimal funksjonsmutasjon (er heterozygote). Behandlingen er ogs\u00e5 godkjent for de som har dobbel F508del-mutasjon (er homozygote). Fra og med 1. juli 2024 er Kaftrio ogs\u00e5 godkjent i Norge for barn i aldersgruppen 2-6 \u00e5r som har minst \u00e9n F508del-mutasjon.<\/p>\n<p>&nbsp;<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<p><span style=\"font-size: medium;\"><strong>Beste behandling for de med \u00e9n F508del og minimal-funksjon<\/strong><\/span><\/p>\n<p>Kaftrio\/Kalydeco er den \u00e5rsaks-korrigerende medikamentelle behandlingen som blant heterozygote med en F508del og en minimalfunksjon-mutasjon (MF-mutasjon) har vist best effekt. Kaftrio \/Kalydeco er derfor et stort gjennombrudd i behandlingen av cystisk fibrose. Minimalfunksjon-mutasjon lager CFTR-proteiner med liten restfunksjon. Kaftrio\/Kalydeco \u00f8ker mengden aktivt CFTR-protein.<\/p>\n<p>[\/et_pb_toggle][\/et_pb_column][et_pb_column type=&raquo;1_3&#8243; _builder_version=&raquo;4.21.0&#8243; _module_preset=&raquo;default&raquo; global_colors_info=&raquo;{}&raquo;][et_pb_toggle title=&raquo;Effekten til Kaftrio\/Kalydeco&raquo; open_toggle_text_color=&raquo;gcid-edcc47c2-e936-4ba2-8e6c-8ca8cb2c2a05&#8243; open_toggle_background_color=&raquo;gcid-9e2f3af2-1007-4221-b250-8e35d98c5991&#8243; closed_toggle_background_color=&raquo;gcid-9e2f3af2-1007-4221-b250-8e35d98c5991&#8243; icon_color=&raquo;gcid-edcc47c2-e936-4ba2-8e6c-8ca8cb2c2a05&#8243; toggle_icon=&raquo;&#x22;||divi||400&#8243; use_icon_font_size=&raquo;on&raquo; icon_font_size=&raquo;18px&raquo; open_icon_color=&raquo;gcid-edcc47c2-e936-4ba2-8e6c-8ca8cb2c2a05&#8243; open_toggle_icon=&raquo;&#x21;||divi||400&#8243; _builder_version=&raquo;4.21.0&#8243; _module_preset=&raquo;default&raquo; title_text_color=&raquo;gcid-edcc47c2-e936-4ba2-8e6c-8ca8cb2c2a05&#8243; title_font=&raquo;|600|||||||&raquo; body_text_color=&raquo;gcid-26e97d0d-b127-4ce1-b597-0df3fb01df24&#8243; body_link_text_color=&raquo;gcid-edcc47c2-e936-4ba2-8e6c-8ca8cb2c2a05&#8243; custom_padding=&raquo;35px||35px||false|false&raquo; border_width_all=&raquo;0px&raquo; locked=&raquo;off&raquo; global_colors_info=&raquo;{%22gcid-edcc47c2-e936-4ba2-8e6c-8ca8cb2c2a05%22:%91%22icon_color%22,%22open_toggle_text_color%22,%22title_text_color%22,%22body_link_text_color%22,%22open_icon_color%22%93,%22gcid-26e97d0d-b127-4ce1-b597-0df3fb01df24%22:%91%22body_text_color%22%93,%22gcid-9e2f3af2-1007-4221-b250-8e35d98c5991%22:%91%22open_toggle_background_color%22,%22closed_toggle_background_color%22%93}&raquo;]<\/p>\n<p>Studier har vist at behandling med Kaftrio\/Kalydeco gir opptil 14 prosentpoeng bedring i lungekapasitet m\u00e5lt ved FEV1 hos heterozygote CF-pasienter sammenliknet med placebo. For de homozygote pasientene viste studien at de fikk en \u00f8kning i lungekapasitet p\u00e5 10 prosentpoeng sammenlignet med de som fikk Symkevi (som er en tidligere anvendt \u00e5rsakskorrigerende behandling).<\/p>\n<p>Kaftrio\/Kalydeco bidrar til en friskere CF-populasjon med mindre kronisk infeksjon og f\u00e6rre forverringer samt bedre ern\u00e6ringsstatus. Vanligste bivirkninger er kviser, hodepine, diar\u00e9, og tetthet i \u00f8vre luftveier. Behandlingen gis som tabletter morgen og kveld.<\/p>\n<p>Behandlingen m\u00e5 f\u00f8lges n\u00f8ye opp av kompetent helsepersonell med hensyn til b\u00e5de effekt og bivirkninger.<\/p>\n<p>[\/et_pb_toggle][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&raquo;1_2,1_2&#8243; _builder_version=&raquo;4.21.0&#8243; _module_preset=&raquo;default&raquo; custom_margin=&raquo;50px|auto||auto|false|false&raquo; custom_margin_tablet=&raquo;50px|auto||auto|false|false&raquo; custom_margin_phone=&raquo;50px|auto||auto|false|false&raquo; custom_margin_last_edited=&raquo;on|desktop&raquo; custom_padding=&raquo;0px|||||&raquo; global_colors_info=&raquo;{}&raquo;][et_pb_column type=&raquo;1_2&#8243; _builder_version=&raquo;4.21.0&#8243; _module_preset=&raquo;default&raquo; global_colors_info=&raquo;{}&raquo;][et_pb_text _builder_version=&raquo;4.21.0&#8243; _module_preset=&raquo;default&raquo; header_font=&raquo;Poppins|600|||||||&raquo; header_text_color=&raquo;gcid-26e97d0d-b127-4ce1-b597-0df3fb01df24&#8243; custom_margin=&raquo;0px||0px||false|false&raquo; custom_padding=&raquo;0px||0px||false|false&raquo; global_colors_info=&raquo;{%22gcid-26e97d0d-b127-4ce1-b597-0df3fb01df24%22:%91%22header_text_color%22%93}&raquo;]<\/p>\n<h1><span style=\"font-size: x-large;\"><strong>600 dagers lang kamp<\/strong><\/span><\/h1>\n<p>[\/et_pb_text][et_pb_text _builder_version=&raquo;4.21.0&#8243; _module_preset=&raquo;default&raquo; text_font=&raquo;Poppins|300|||||||&raquo; text_text_color=&raquo;gcid-26e97d0d-b127-4ce1-b597-0df3fb01df24&#8243; text_font_size=&raquo;16px&raquo; text_line_height=&raquo;1.8em&raquo; global_colors_info=&raquo;{%22gcid-26e97d0d-b127-4ce1-b597-0df3fb01df24%22:%91%22text_text_color%22%93}&raquo;]<\/p>\n<p>Kampen for \u00e5 f\u00e5 Kaftrio\/Kalydeco godkjent i Norge var lang og krevende, og tok mer enn 600 dager. Norsk forening for cystisk fibrose sto i barrikadene gjennom hele prosessen, og vi kan n\u00e5 med stolthet se tilbake p\u00e5 resultatene av v\u00e5rt arbeid. Godkjenningen i 2022 for pasienter fra 6 \u00e5r og oppover, samt den viktige indikasjonsutvidelsen i 2024 for barn i aldersgruppen 2-6 \u00e5r, representerer store seire for CF-milj\u00f8et.<\/p>\n<p>Disse gjennombruddene er et resultat av v\u00e5r dedikasjon og utholdenhet i m\u00f8te med betydelige utfordringer. Om behandlingen i fremtiden blir godkjent for andre mutasjonskombinasjoner, er fortsatt usikkert. P\u00e5g\u00e5ende legemiddelutvikling og forskning gir imidlertid h\u00e5p for de som i dag faller utenfor indikasjonene for Kaftrio\/Kalydeco.<\/p>\n<p>Som <a href=\"https:\/\/nfcf.portal.styreweb.com\/arrangement\/ArrangementSession?ID=Innmelding\">medlem<\/a> i Norsk forening for cystisk fibrose st\u00f8tter du v\u00e5r innsats i disse viktige kampene. Din st\u00f8tte styrker v\u00e5r felles stemme overfor politikere og beslutningstakere, og hjelper oss \u00e5 oppn\u00e5 slike betydningsfulle resultater for deg og din familie.<\/p>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&raquo;1_2&#8243; _builder_version=&raquo;4.21.0&#8243; _module_preset=&raquo;default&raquo; global_colors_info=&raquo;{}&raquo;][et_pb_image src=&raquo;https:\/\/cfnorge.bwod.dev\/wp-content\/uploads\/2024\/06\/kaftrio.png&raquo; title_text=&raquo;kaftrio&raquo; _builder_version=&raquo;4.21.0&#8243; _module_preset=&raquo;default&raquo; custom_margin=&raquo;||-7px|||&raquo; global_colors_info=&raquo;{}&raquo;][\/et_pb_image][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&raquo;1&#8243; disabled_on=&raquo;on|on|off&raquo; _builder_version=&raquo;4.21.0&#8243; _module_preset=&raquo;default&raquo; background_color=&raquo;gcid-f60bfea8-f451-489d-8bfd-27e12ee36365&#8243; custom_padding=&raquo;||0px||false|false&raquo; global_colors_info=&raquo;{%22gcid-f60bfea8-f451-489d-8bfd-27e12ee36365%22:%91%22background_color%22%93}&raquo;][et_pb_row column_structure=&raquo;1_2,1_2&#8243; use_custom_gutter=&raquo;on&raquo; gutter_width=&raquo;1&#8243; _builder_version=&raquo;4.21.0&#8243; _module_preset=&raquo;default&raquo; custom_margin=&raquo;||0px||false|false&raquo; custom_padding=&raquo;||0px||false|false&raquo; global_colors_info=&raquo;{}&raquo;][et_pb_column type=&raquo;1_2&#8243; _builder_version=&raquo;4.21.0&#8243; _module_preset=&raquo;default&raquo; global_colors_info=&raquo;{}&raquo;][et_pb_image src=&raquo;https:\/\/cfnorge.bwod.dev\/wp-content\/uploads\/2023\/08\/Stott-oss-illustrasjon-CF-1.png&raquo; title_text=&raquo;St\u00f8tt-oss-illustrasjon-CF&raquo; _builder_version=&raquo;4.21.0&#8243; _module_preset=&raquo;default&raquo; width=&raquo;65%&raquo; module_alignment=&raquo;center&raquo; global_colors_info=&raquo;{}&raquo;][\/et_pb_image][\/et_pb_column][et_pb_column type=&raquo;1_2&#8243; _builder_version=&raquo;4.21.0&#8243; _module_preset=&raquo;default&raquo; global_colors_info=&raquo;{}&raquo;][et_pb_text _builder_version=&raquo;4.21.0&#8243; _module_preset=&raquo;default&raquo; header_2_font=&raquo;Poppins|600|||||||&raquo; header_2_text_color=&raquo;gcid-26e97d0d-b127-4ce1-b597-0df3fb01df24&#8243; header_2_font_size=&raquo;30px&raquo; header_3_font=&raquo;Poppins||||||||&raquo; header_3_text_color=&raquo;gcid-26e97d0d-b127-4ce1-b597-0df3fb01df24&#8243; header_3_font_size=&raquo;20px&raquo; header_3_line_height=&raquo;1.5em&raquo; custom_margin=&raquo;74px||18px|||&raquo; global_colors_info=&raquo;{%22gcid-26e97d0d-b127-4ce1-b597-0df3fb01df24%22:%91%22header_2_text_color%22,%22header_3_text_color%22%93}&raquo;]<\/p>\n<h2>St\u00f8tt oss<\/h2>\n<h3>Vi er veldig glade for alle sm\u00e5<br \/>\nog store gaver til v\u00e5rt arbeid.<\/h3>\n<p>[\/et_pb_text][et_pb_button button_url=&raquo;@ET-DC@eyJkeW5hbWljIjp0cnVlLCJjb250ZW50IjoicG9zdF9saW5rX3VybF9wYWdlIiwic2V0dGluZ3MiOnsicG9zdF9pZCI6IjQ1NyJ9fQ==@&raquo; button_text=&raquo;Les hvordan her&raquo; _builder_version=&raquo;4.21.0&#8243; _dynamic_attributes=&raquo;button_url&raquo; _module_preset=&raquo;default&raquo; custom_button=&raquo;on&raquo; button_text_size=&raquo;16px&raquo; button_text_color=&raquo;#FFFFFF&raquo; button_bg_color=&raquo;gcid-edcc47c2-e936-4ba2-8e6c-8ca8cb2c2a05&#8243; button_border_width=&raquo;0px&raquo; button_border_radius=&raquo;100px&raquo; global_colors_info=&raquo;{%22gcid-edcc47c2-e936-4ba2-8e6c-8ca8cb2c2a05%22:%91%22button_bg_color%22%93}&raquo;][\/et_pb_button][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&raquo;1&#8243; disabled_on=&raquo;off|off|on&raquo; _builder_version=&raquo;4.21.0&#8243; _module_preset=&raquo;default&raquo; background_color=&raquo;gcid-f60bfea8-f451-489d-8bfd-27e12ee36365&#8243; custom_padding=&raquo;||0px||false|false&raquo; global_colors_info=&raquo;{%22gcid-f60bfea8-f451-489d-8bfd-27e12ee36365%22:%91%22background_color%22%93}&raquo;][et_pb_row use_custom_gutter=&raquo;on&raquo; gutter_width=&raquo;1&#8243; _builder_version=&raquo;4.21.0&#8243; _module_preset=&raquo;default&raquo; custom_margin=&raquo;||0px||false|false&raquo; custom_padding=&raquo;8px||0px||false|false&raquo; global_colors_info=&raquo;{}&raquo;][et_pb_column type=&raquo;4_4&#8243; _builder_version=&raquo;4.21.0&#8243; _module_preset=&raquo;default&raquo; global_colors_info=&raquo;{}&raquo;][et_pb_text _builder_version=&raquo;4.21.0&#8243; _module_preset=&raquo;default&raquo; header_2_font=&raquo;Poppins|600|||||||&raquo; header_2_text_color=&raquo;gcid-26e97d0d-b127-4ce1-b597-0df3fb01df24&#8243; header_2_font_size=&raquo;30px&raquo; header_3_font=&raquo;Poppins||||||||&raquo; header_3_text_color=&raquo;gcid-26e97d0d-b127-4ce1-b597-0df3fb01df24&#8243; header_3_font_size=&raquo;20px&raquo; header_3_line_height=&raquo;1.5em&raquo; custom_margin=&raquo;7px||18px|||&raquo; global_colors_info=&raquo;{%22gcid-26e97d0d-b127-4ce1-b597-0df3fb01df24%22:%91%22header_2_text_color%22,%22header_3_text_color%22%93}&raquo;]<\/p>\n<h2>St\u00f8tt oss<\/h2>\n<h3>Vi er veldig glade for alle sm\u00e5<br \/>\nog store gaver til v\u00e5rt arbeid.<\/h3>\n<p>[\/et_pb_text][et_pb_button button_url=&raquo;@ET-DC@eyJkeW5hbWljIjp0cnVlLCJjb250ZW50IjoicG9zdF9saW5rX3VybF9wYWdlIiwic2V0dGluZ3MiOnsicG9zdF9pZCI6IjQ1NyJ9fQ==@&raquo; button_text=&raquo;Les hvordan her&raquo; _builder_version=&raquo;4.21.0&#8243; _dynamic_attributes=&raquo;button_url&raquo; _module_preset=&raquo;default&raquo; custom_button=&raquo;on&raquo; button_text_size=&raquo;16px&raquo; button_text_color=&raquo;#FFFFFF&raquo; button_bg_color=&raquo;gcid-edcc47c2-e936-4ba2-8e6c-8ca8cb2c2a05&#8243; button_border_width=&raquo;0px&raquo; button_border_radius=&raquo;100px&raquo; global_colors_info=&raquo;{%22gcid-edcc47c2-e936-4ba2-8e6c-8ca8cb2c2a05%22:%91%22button_bg_color%22%93}&raquo;][\/et_pb_button][et_pb_image src=&raquo;https:\/\/www.cfnorge.no\/wp-content\/uploads\/2023\/08\/Stott-oss-illustrasjon-CF-1.png&raquo; title_text=&raquo;St\u00f8tt-oss-illustrasjon-CF&raquo; _builder_version=&raquo;4.21.0&#8243; _module_preset=&raquo;default&raquo; width=&raquo;65%&raquo; width_tablet=&raquo;50%&raquo; width_phone=&raquo;58%&raquo; width_last_edited=&raquo;on|phone&raquo; module_alignment=&raquo;right&raquo; custom_margin=&raquo;||||false|false&raquo; custom_margin_tablet=&raquo;-20px||||false|false&raquo; custom_margin_phone=&raquo;0px||||false|false&raquo; custom_margin_last_edited=&raquo;on|tablet&raquo; custom_padding_tablet=&raquo;||||false|false&raquo; custom_padding_phone=&raquo;||||false|false&raquo; custom_padding_last_edited=&raquo;on|tablet&raquo; global_colors_info=&raquo;{}&raquo;][\/et_pb_image][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Kaftrio ble endelig godkjent i Norge 25. april 2022 ved et vedtak i Beslutningsforum. Kaftrio er en innovativ \u00e5rsakskorrigerende behandling for cystisk fibrose. Behandlingen med Kaftrio gir opptil 14 prosentpoeng bedring i lungekapasitet.  <\/p>","protected":false},"author":1,"featured_media":0,"parent":265,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"class_list":["post-436","page","type-page","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Slik er behadlingen for CF med Kaftrio | CF Norge<\/title>\n<meta name=\"description\" content=\"Kaftrio for Cyctisk Fiberose \u2013 CF Norge. Kaftrio er en behandling for cystisk fibrose. I 2022 ble CFTR-modulatoren endelig godkjent i Norge.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cfnorge.no\/en\/cystisk-fibrose\/slik-er-behadlingen-for-cf-med-kaftrio\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Slik er behadlingen for CF med Kaftrio | CF Norge\" \/>\n<meta property=\"og:description\" content=\"Kaftrio for Cyctisk Fiberose \u2013 CF Norge. Kaftrio er en behandling for cystisk fibrose. I 2022 ble CFTR-modulatoren endelig godkjent i Norge.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cfnorge.no\/en\/cystisk-fibrose\/slik-er-behadlingen-for-cf-med-kaftrio\/\" \/>\n<meta property=\"og:site_name\" content=\"CF Norge\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-10T13:59:08+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.cfnorge.no\\\/cystisk-fibrose\\\/slik-er-behadlingen-for-cf-med-kaftrio\\\/\",\"url\":\"https:\\\/\\\/www.cfnorge.no\\\/cystisk-fibrose\\\/slik-er-behadlingen-for-cf-med-kaftrio\\\/\",\"name\":\"Slik er behadlingen for CF med Kaftrio | CF Norge\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.cfnorge.no\\\/#website\"},\"datePublished\":\"2023-09-14T13:26:37+00:00\",\"dateModified\":\"2025-11-10T13:59:08+00:00\",\"description\":\"Kaftrio for Cyctisk Fiberose \u2013 CF Norge. Kaftrio er en behandling for cystisk fibrose. I 2022 ble CFTR-modulatoren endelig godkjent i Norge.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.cfnorge.no\\\/cystisk-fibrose\\\/slik-er-behadlingen-for-cf-med-kaftrio\\\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.cfnorge.no\\\/cystisk-fibrose\\\/slik-er-behadlingen-for-cf-med-kaftrio\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.cfnorge.no\\\/cystisk-fibrose\\\/slik-er-behadlingen-for-cf-med-kaftrio\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hjem\",\"item\":\"https:\\\/\\\/www.cfnorge.no\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cystisk fibrose\",\"item\":\"https:\\\/\\\/www.cfnorge.no\\\/cystisk-fibrose\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Slik er behadlingen for CF med Kaftrio\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.cfnorge.no\\\/#website\",\"url\":\"https:\\\/\\\/www.cfnorge.no\\\/\",\"name\":\"CF Norge\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.cfnorge.no\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.cfnorge.no\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.cfnorge.no\\\/#organization\",\"name\":\"CF Norge\",\"url\":\"https:\\\/\\\/www.cfnorge.no\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\\\/\\\/www.cfnorge.no\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.cfnorge.no\\\/wp-content\\\/uploads\\\/2024\\\/06\\\/CF-Horisontal-logo-2.png\",\"contentUrl\":\"https:\\\/\\\/www.cfnorge.no\\\/wp-content\\\/uploads\\\/2024\\\/06\\\/CF-Horisontal-logo-2.png\",\"width\":12334,\"height\":3827,\"caption\":\"CF Norge\"},\"image\":{\"@id\":\"https:\\\/\\\/www.cfnorge.no\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Slik er behadlingen for CF med Kaftrio | CF Norge","description":"Kaftrio for Cyctisk Fiberose \u2013 CF Norge. Kaftrio er en behandling for cystisk fibrose. I 2022 ble CFTR-modulatoren endelig godkjent i Norge.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cfnorge.no\/en\/cystisk-fibrose\/slik-er-behadlingen-for-cf-med-kaftrio\/","og_locale":"en_GB","og_type":"article","og_title":"Slik er behadlingen for CF med Kaftrio | CF Norge","og_description":"Kaftrio for Cyctisk Fiberose \u2013 CF Norge. Kaftrio er en behandling for cystisk fibrose. I 2022 ble CFTR-modulatoren endelig godkjent i Norge.","og_url":"https:\/\/www.cfnorge.no\/en\/cystisk-fibrose\/slik-er-behadlingen-for-cf-med-kaftrio\/","og_site_name":"CF Norge","article_modified_time":"2025-11-10T13:59:08+00:00","twitter_card":"summary_large_image","twitter_misc":{"Estimated reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.cfnorge.no\/cystisk-fibrose\/slik-er-behadlingen-for-cf-med-kaftrio\/","url":"https:\/\/www.cfnorge.no\/cystisk-fibrose\/slik-er-behadlingen-for-cf-med-kaftrio\/","name":"Slik er behadlingen for CF med Kaftrio | CF Norge","isPartOf":{"@id":"https:\/\/www.cfnorge.no\/#website"},"datePublished":"2023-09-14T13:26:37+00:00","dateModified":"2025-11-10T13:59:08+00:00","description":"Kaftrio for Cyctisk Fiberose \u2013 CF Norge. Kaftrio er en behandling for cystisk fibrose. I 2022 ble CFTR-modulatoren endelig godkjent i Norge.","breadcrumb":{"@id":"https:\/\/www.cfnorge.no\/cystisk-fibrose\/slik-er-behadlingen-for-cf-med-kaftrio\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cfnorge.no\/cystisk-fibrose\/slik-er-behadlingen-for-cf-med-kaftrio\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.cfnorge.no\/cystisk-fibrose\/slik-er-behadlingen-for-cf-med-kaftrio\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hjem","item":"https:\/\/www.cfnorge.no\/"},{"@type":"ListItem","position":2,"name":"Cystisk fibrose","item":"https:\/\/www.cfnorge.no\/cystisk-fibrose\/"},{"@type":"ListItem","position":3,"name":"Slik er behadlingen for CF med Kaftrio"}]},{"@type":"WebSite","@id":"https:\/\/www.cfnorge.no\/#website","url":"https:\/\/www.cfnorge.no\/","name":"CF Norge","description":"","publisher":{"@id":"https:\/\/www.cfnorge.no\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cfnorge.no\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"},{"@type":"Organization","@id":"https:\/\/www.cfnorge.no\/#organization","name":"CF Norge","url":"https:\/\/www.cfnorge.no\/","logo":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/www.cfnorge.no\/#\/schema\/logo\/image\/","url":"https:\/\/www.cfnorge.no\/wp-content\/uploads\/2024\/06\/CF-Horisontal-logo-2.png","contentUrl":"https:\/\/www.cfnorge.no\/wp-content\/uploads\/2024\/06\/CF-Horisontal-logo-2.png","width":12334,"height":3827,"caption":"CF Norge"},"image":{"@id":"https:\/\/www.cfnorge.no\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.cfnorge.no\/en\/wp-json\/wp\/v2\/pages\/436","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cfnorge.no\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.cfnorge.no\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.cfnorge.no\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cfnorge.no\/en\/wp-json\/wp\/v2\/comments?post=436"}],"version-history":[{"count":32,"href":"https:\/\/www.cfnorge.no\/en\/wp-json\/wp\/v2\/pages\/436\/revisions"}],"predecessor-version":[{"id":2228,"href":"https:\/\/www.cfnorge.no\/en\/wp-json\/wp\/v2\/pages\/436\/revisions\/2228"}],"up":[{"embeddable":true,"href":"https:\/\/www.cfnorge.no\/en\/wp-json\/wp\/v2\/pages\/265"}],"wp:attachment":[{"href":"https:\/\/www.cfnorge.no\/en\/wp-json\/wp\/v2\/media?parent=436"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}